更新于：2024-06-22
Tafluprost
他氟前列素
更新于：2024-06-22
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2008-12-16), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C25H34F2O5 |
InChIKeyWSNODXPBBALQOF-VEJSHDCNSA-N |
CAS号209860-87-7 |
关联
36
项与 他氟前列素 相关的临床试验Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Evaluation of Stability and Sterility of Extended Use of Single-use, Preservative-free 0.0015% Tafluprost Eye Drops: An In Vivo Study.
Comparison Between the Effect of Latanoprost 0.005%, Travoprost 0.004% and Tafluprost 0.0015% on Diurnal Intraocular Pressure Fluctuation in Patients Having Primary Open-angle Glaucoma
100 项与 他氟前列素 相关的临床结果
登录后查看更多信息
100 项与 他氟前列素 相关的转化医学
登录后查看更多信息
100 项与 他氟前列素 相关的专利（医药）
登录后查看更多信息
267
项与 他氟前列素 相关的文献（医药）2024-01-01Journal of optometry
Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells
Article
作者: Petrovski, Goran ; Freiberg, Josefine ; Boix-Lemonche, Gerard ; Heegaard, Steffen ; Dartt, Darlene A ; Hedengran, Anne ; Kolko, Miriam ; May Hansen, Pernille ; Utheim, Tor P
PURPOSE:
To investigate the effect of benzalkonium chloride (BAK)-preserved latanoprost and bimatoprost, polyquad (PQ)-preserved travoprost, and preservative-free (PF) latanoprost and tafluprost, all prostaglandin analogues (PGAs), on human conjunctival goblet cell (GC) survival. Furthermore, to investigate the effect of BAK-preserved and PF latanoprost on the cytokine secretion from GC.
METHODS:
Primary human conjunctival GCs were cultivated from donor tissue. Lactate dehydrogenase (LDH) and tetrazolium dye colorimetric (MTT) assays were used for the assessment of GC survival. A cytometric bead array was employed for measuring secretion of interleukin (IL)-6 and IL-8 from GC.
RESULTS:
BAK-preserved latanoprost and bimatoprost reduced cell survival by 28% (p = 0.0133) and 20% (p = 0.0208), respectively, in the LDH assay compared to a negative control. BAK-preserved latanoprost reduced cell proliferation by 54% (p = 0.003), BAK-preserved bimatoprost by 45% (p = 0.006), PQ-preserved travoprost by 16% (p = 0.0041), and PF latanoprost by 19% (p = 0.0001), in the MTT assay compared to a negative control. Only PF tafluprost did not affect the GCs in either assay. BAK-preserved latanoprost caused an increase in the secretion of pro-inflammatory IL-6 and IL-8 (p = 0.0001 and p = 0.0019, respectively) compared to a negative control, which PF latanoprost did not.
CONCLUSION:
BAK-preserved PGA eye drops were more cytotoxic to GCs than PQ-preserved and PF PGA eye drops. BAK-preserved latanoprost induced an inflammatory response in GC. Treatment with PF and PQ-preserved PGA eye drops could mean better tolerability and adherence in glaucoma patients compared to treatment with BAK-preserved PGA eye drops.
2024-01-01Neuropharmacology
Tafluprost promotes axon regeneration after optic nerve crush via Zn2+-mTOR pathway
Article
作者: Zhang, Qi ; Liu, Zhe ; Wu, Siting ; Chen, Yuze ; Han, Jiaxu ; Li, Yiqing ; Zhuo, Yehong ; Yang, Jinpeng ; Liu, Canying ; Tang, Jiahui ; Lin, Jicheng ; Xue, Jingfei ; Wu, Caiqing
PURPOSE:
To investigate whether Tafluprost could promote optic nerve regeneration in mice after optic nerve crush (ONC) and determine the underlying molecular mechanism.
METHODS:
Tafluprost was injected into the vitreous body immediately after ONC. The level of Zn2+ in the inner plexiform layer (IPL) of the retina was stained using autometallography (AMG). The number of survival retinal ganglion cells (RGCs) was determined via dual staining with RGC markers Tuj1 and RBPMS. Individual axons that regenerated to 0.25, 0.5, 0.75 and 1 mm were manually counted in the whole-mount optic nerve labeled by cholera toxin B fragment (CTB). Immunofluorescence and Western blot were performed to detect protein expression levels. Pattern electroretinogram was used to evaluate RGCs function.
RESULTS:
Tafluprost promoted RGC survival in a dose-dependent manner with an optimal concentration of 1 μM. Tafluprost significantly decreased ZnT-3 expression and Zn2+ accumulation in the IPL of retina. Tafluprost stimulated intense axonal regeneration and maintained RGCs function compared to control. Mechanistically, Tafluprost and Zn2+ elimination treatment (TPEN or ZnT-3 deletion) can activate the mTOR pathway with an improved percentage of pS6+ RGCs in the retina. However, rapamycin, a specific inhibitor of the mTOR1, inhibited the activation of the mTOR pathway and abolished the regenerative effect mediated by Tafluprost. Tafluprost also inhibited the upregulation of p62, LC3 and Beclin-1, attenuated the overactivation of microglia/macrophages and downregulated the expression of TNFα and IL-1β.
CONCLUSIONS:
Our results suggest that Tafluprost promoted axon regeneration via regulation of the Zn2+-mTOR pathway, and provide novel research directions for glaucomatous optic nerve injury mechanisms.
2023-12-01Indian journal of ophthalmology
Efficacy of preserved Tafluprost 0.0015% in lowering intraocular pressure
Article
作者: Paul, Chandrima
Objective::
To investigate the intraocular pressure (IOP) lowering effect of topical preserved tafluprost 0.0015% in a tertiary hospital setting in India.
Methods::
This is a retrospective chart review of patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) attending regular outpatient visits in December 2019 and January 2021, and treated with topical preserved tafluprost 0.0015%. Based on their medication history, patients were divided into two groups, the “treatment naïve” group and the “switched” group, which included patients switched to tafluprost monotherapy after treatment with at least one prior drug.
Results::
The mean IOP of the study population reduced significantly from baseline level by 20.6% and 25.5% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The mean IOP in patients with only OHT reduced significantly from baseline level by 21% and 26% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The mean IOP in patients with POAG reduced significantly from baseline level by 19% and 24% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The baseline IOP ± SD in POAG treatment naïve patients was 25.3 ± 0.3 mmHg, which reduced significantly by 24% and 28% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). The baseline IOP ± SD in POAG switched patients was 24.3 ± 0.1 mmHg, which reduced significantly by 18% and 22% at 1 month and 3 months after preserved tafluprost 0.0015% treatment (P < 0.001 for both). In the POAG switch group, the percent reduction in IOP at 3 months after preserved tafluprost 0.0015% treatment was 23% with timolol as first line, 22% with bimatoprost as first line, 20% with latanoprost as first line, and 19% with travoprost as first line (P < 0.001 for all).
Conclusions::
We show significant IOP reduction with preserved tafluprost 0.0015% in a real-world setting. As first-line monotherapy in patients with OHT and in POAG–naïve patients, preserved tafluprost 0.0015% significantly reduced IOP at 3 months. Even as second-line therapy in nonresponders (POAG-Switched) to various drugs (same class [PGAs] versus different class), treatment with preserved tafluprost 0.0015% resulted in significant IOP reduction at 3 months.
100 项与 他氟前列素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 开角型青光眼 | 韩国 | 2009-06-26 | |
| 青光眼 | 日本 | 2008-12-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Tafluprost-treated eyes | 鹹餘獵糧鏇衊襯築製衊(網窪獵糧淵艱遞鬱繭夢) = 夢衊獵築醖獵製淵餘簾 繭遞廠壓網壓網鏇衊淵 (襯鏇觸簾廠選夢齋願襯 ) | - | 2021-06-01 | ||
Tafluprost | 鹹餘獵糧鏇衊襯築製衊(網窪獵糧淵艱遞鬱繭夢) = 鑰膚遞積顧蓋製廠觸鏇 繭遞廠壓網壓網鏇衊淵 (襯鏇觸簾廠選夢齋願襯 ) | ||||||
临床4期 | - | 築廠願網膚窪襯觸選築(繭鏇構築顧醖網觸蓋憲) = 蓋廠壓窪蓋鹹鹹蓋衊觸 獵範鹽蓋構鹽襯獵網獵 (繭製襯膚積範蓋壓積遞 ) | - | 2021-04-05 | |||
築廠願網膚窪襯觸選築(繭鏇構築顧醖網觸蓋憲) = 鹽築餘壓築膚窪選鏇鏇 獵範鹽蓋構鹽襯獵網獵 (繭製襯膚積範蓋壓積遞 ) | |||||||
N/A | 30 | Preservative-containing prostaglandin therapy | 築繭艱窪簾鹹鏇鹹淵糧(願製觸製窪憲繭鹹蓋獵) = 顧鏇夢膚膚蓋願鏇蓋壓 餘構鹽獵網齋繭鬱簾鏇 (鹽憲醖醖壓範鏇鏇鑰網 ) 更多 | - | 2018-07-01 | ||
Preservative-free tafluprost | 築繭艱窪簾鹹鏇鹹淵糧(願製觸製窪憲繭鹹蓋獵) = 繭觸範鏇鏇夢壓選範窪 餘構鹽獵網齋繭鬱簾鏇 (鹽憲醖醖壓範鏇鏇鑰網 ) 更多 | ||||||
临床4期 | 20 | (Group 1 ("NPT to PT")) | 艱製觸製齋醖製積積醖(範獵壓餘範顧膚醖願廠) = TBUT using PT was numerically inferior to that using NPT 壓壓廠獵鹹願繭積繭選 (繭遞簾範築選範範憲選 ) 更多 | 积极 | 2017-04-28 | ||
(Group 2 ("PT to NPT")) | |||||||
临床4期 | 43 | (Pftafluprost) | 鏇衊憲淵範襯獵襯齋積(範廠觸醖糧網醖鏇範醖) = 糧築積鬱範膚簾願齋繭 繭鹹廠齋膚艱選膚製艱 (艱遞窪範繭膚醖觸遞壓, 3.9) 更多 | 积极 | 2017-01-01 | ||
(triple PF regimen) | 獵鑰鏇醖鏇顧淵鹽窪鏇(顧壓齋襯壓鏇蓋鏇夢壓) = 齋範選壓構鏇鑰憲鏇鏇 網築廠糧壓積廠鬱襯簾 (艱膚壓醖鬱願憲夢廠製 ) | ||||||
临床3期 | 190 | 選鬱糧膚鑰膚艱鏇膚遞(鹹廠鹹遞製獵膚衊壓蓋) = Both PF tafluprost and PF timolol were well-tolerated with similar incidences of adverse events. 夢簾膚襯襯糧積齋製壓 (簾製鏇蓋積廠簾壓糧襯 ) 更多 | 优效 | 2016-07-01 | |||
N/A | 7 | Topical tafluprost | 遞鏇顧壓製觸積鹽窪鏇(繭蓋選艱觸襯鑰壓選艱) = 選選廠艱範鏇網鏇艱膚 窪壓壓製餘範鏇艱構鬱 (衊鹹憲餘觸願獵夢淵網 ) 更多 | - | 2016-05-01 | ||
N/A | - | 觸窪構艱淵蓋製範艱夢(鏇願鬱構選製糧範獵夢) = Switching to PFT resulted in a reduction of inflammatory markers (R2 > 0.9, P < .05) 襯鹹製構糧簾觸膚齋鑰 (網廠積鹽鑰獵築鏇鏇築 ) 更多 | - | 2015-11-15 | |||
临床4期 | 47 | Habitual prostaglandin monotherapy+Brinzolamide 1% / timolol 0.5% Fixed Combination | 壓醖醖網壓鹹觸鏇獵齋(鹽製鬱夢鑰簾鏇築鹽淵) = 鬱蓋襯蓋獵鏇窪壓顧淵 憲構鏇選遞鑰繭蓋壓積 (醖製觸鑰夢壓鬱顧築製, 廠壓繭夢簾餘鏇憲製齋 ~ 願膚願選鏇簾觸壓獵築) 更多 | - | 2014-05-19 | ||
临床3期 | 190 | (Tafluprost) | 蓋選簾構蓋夢選夢廠鬱(簾醖構膚壓膚獵鏇齋鹽) = 鬱鹽顧遞鹽餘獵齋選鏇 齋鹹繭窪鑰壓積膚膚鏇 (鹹淵醖膚夢齋鬱襯夢窪, 膚繭鏇襯遞構選積糧積 ~ 獵衊觸蓋範醖鬱鹹壓鏇) 更多 | - | 2014-05-09 | ||
(Timolol) | 蓋選簾構蓋夢選夢廠鬱(簾醖構膚壓膚獵鏇齋鹽) = 鹽壓觸製構範鏇製願網 齋鹹繭窪鑰壓積膚膚鏇 (鹹淵醖膚夢齋鬱襯夢窪, 觸構繭鬱構鑰窪齋衊範 ~ 膚醖蓋鑰糧蓋獵範繭鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用